Perceptive Advisors’s Stemline Therapeutics, Inc. STML Stock Holding History

Perceptive Advisors’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-10,702	Closed	-$115K	–	223
2016 Q4	$115K	Hold	10,702	–	–	0.01%	150
2016 Q3	$116K	Sell	10,702 -67,901	-86%	-$552K	0.01%	176
2016 Q2	$532K	Hold	78,603	–	–	0.04%	114
2016 Q1	$366K	Hold	78,603	–	–	0.03%	139
2015 Q4	$496K	Hold	78,603	–	–	0.04%	101
2015 Q3	$694K	Sell	78,603 -642	-0.8%	-$6.74K	0.06%	105
2015 Q2	$933K	Hold	79,245	–	–	0.06%	120
2015 Q1	$1.15M	Buy	+79,245	New	+$1.21M	0.09%	98
2014 Q2	–	Sell	-38	Closed	-$1K	–	152
2014 Q1	$1K	Hold	38	–	–	﹤0.01%	127
2013 Q4	$1K	Sell	38 -90,170	-100%	-$2.41M	﹤0.01%	109
2013 Q3	$4.09M	Sell	90,208 -501,442	-85%	-$16.4M	0.33%	44
2013 Q2	$14.1M	Buy	+591,650	New	+$9.42M	1.42%	15

Other funds holding STML

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

IBT

International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

Perceptive Advisors's STML Position: Q1 2017 in Review

Perceptive Advisors sold out of Stemline Therapeutics, Inc. (STML) in Q1 2017, closing a stake of 10,702 shares — an estimated $115K sold.

Perceptive Advisors first reported a position in STML in Q2 2013 and held it in 12 quarters. The position peaked at $14.1M in Q2 2013. 75 funds tracked by Wall St. Rank hold STML as of Q1 2017.

Perceptive Advisors reported no remaining Stemline Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
Perceptive Advisors sold 10,702 Stemline Therapeutics, Inc. shares in Q1 2017, an estimated $115K.
Perceptive Advisors first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 12 quarters.
Perceptive Advisors's Stemline Therapeutics, Inc. position peaked at $14.1M in Q2 2013.
75 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2017.

Based on Perceptive Advisors's 13F filing for Q1 2017, filed 15 May 2017.